Memorial Sloan Kettering Cancer Center Extends Allscripts Sunrise™ Agreement

CHICAGO–(BUSINESS WIRE)–#healthIT–Allscripts Healthcare Solutions (NASDAQ: MDRX) today announced that Memorial Sloan Kettering Cancer Center (MSK), has extended its engagement with Allscripts Sunrise™ through 2026.

Allscripts Sunrise is an integrated electronic health record that can connect all aspects of care. As an evidence-based single platform, Sunrise has integrated analytics that can support core care venues across the enterprise.

“The Allscripts Sunrise platform has been a key component in our clinical platform for two decades,” said Memorial Sloan Kettering Cancer Center’s Chief Operating Officer, Kathryn Martin. “We look forward to continued collaboration with the Health IT company, working to meet the needs of our clinicians and, most importantly, our patients.”

“We’re honored to continue our work with Memorial Sloan Kettering Cancer Center, the largest and oldest private cancer center in the world,” said Allscripts CEO Paul Black. “Our more than 20-year relationship has helped many patients within the cancer community receive world-class care and we’re certain that the cancer center’s extension of its Sunrise engagement will be the right fit for its future success.”

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

 

Contacts

For more information contact:
Investors:

Stephen Shulstein

312-386-6735

Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com

Staff

Recent Posts

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

7 minutes ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

7 minutes ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

7 minutes ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

7 minutes ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

7 minutes ago

PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics

BELFAST, Northern Ireland  , Jan. 12, 2026 /PRNewswire/ -- PulseAI, a rapidly emerging leader in…

8 minutes ago